Times BeatsBusiness and general news releases, as issued

Press Release · IceCure Medical

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2026: 83% Year-Over-Year Growth in U.S. Sales and Major Growth in U.S. Commercial Reach to 21 States

NASDAQICCM

Distributed by Times Beats · Originally issued via PR Newswire

CAESAREA, Israel, Nov. 18, 2026 — IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported its financial and operating results as of and for the nine months ended September 30, 2026.

Third Quarter 2026 Operational and Clinical Highlights

  • 83% Growth in U.S. Sales: U.S. sales of ProSense® and its cryoprobes doubled year over year during the first nine months of 2026 compared to the same period in 2025.
  • 26% Year-Over-Year Revenue Growth: Total revenues for the first nine months of 2026 increased to approximately $2.6 million, compared to $2.1 million in the corresponding period of 2025.
  • Expanded U.S. Commercial Reach: The Company's commercial presence expanded from 11 states in the third quarter of 2025 to 21 states in the third quarter of 2026.
  • Continued Progress in the ChoICE Study: The Company's post-marketing study (the "ChoICE" Study") evaluating ProSense® cryoablation for the local treatment of low-risk breast cancer launched the first clinical sites after Institutional Review Board ("IRB") approval at West Cancer Center & Research Institute (the "West Cancer Center") in Germantown, TN and Adventist Health Glendale in Glendale, CA.
  • International Commercial and Regulatory Progress: Received regulatory approval from China's National Medical Products Administration to market ProSense® as a Class III medical device and signed an exclusive distribution agreement for ProSense® cryoablation systems in the Netherlands.

"We believe the first nine months of 2026 demonstrate the progress we made in translating our regulatory and clinical achievements into commercial growth, particularly in the United States. U.S. sales increased 83% year over year, while our commercial reach expanded from 11 to 21 states during the third quarter of 2026. At the same time, we are building the clinical foundation for broader adoption of ProSense® through the ChoICE Study. We believe these developments position us to continue driving physician adoption and expanding patient access to ProSense®," said Eyal Shamir, Chief Executive Officer of IceCure Medical.

ChoICE Study Moving Forward:

Subsequent to the end of the third quarter of 2026, IceCure announced additional progress in its ChoICE Study:

  • Three clinical sites joined the Company's study, including Legacy Health in Portland, Oregon.
  • The Company announced the enrollment of the first two patients in the ChoICE Study at two U.S. clinical sites: West Cancer Center in Tennessee and Adventist Health Glendale in California.
  • The Company announced the successful completion of the first ProSense® cryoablation treatment in the ChoICE Study. The first patient was treated at West Cancer Center in Germantown, Tennessee, by Dr. Richard E. Fine, MD, FACS.

Additional Third Quarter of 2026 Successes:

  • Expanded U.S. Commercial Team: Strengthened the U.S. sales and marketing organization by adding dedicated professionals in key territories, including New York, Southern California and the Midwest, and Florida, as well as additional clinical support personnel to support physician training and adoption of ProSense®.
  • Participation in Leading Medical Events: Participated in key medical and industry events, including Aptitude Health's Targeted Medical Education ("TME") Take the Lead in Breast Cancer Fall Summit 2026 in New Orleans, LA and the 2026 European Society of Breast Imaging ("EUSOBI") Congress in Maastricht, Netherlands, engaging with leading breast cancer specialists and the broader medical community.
  • Strengthened Clinical Evidence: Highlighted two new peer-reviewed scientific publications supporting the role of cryoablation in breast cancer treatment de-escalation, including publications addressing early-stage breast cancer and axillary lymph node metastases.
  • Professional Recognition of Cryoablation: The Society of Interventional Oncology ("SIO") submitted a formal petition to the National Comprehensive Cancer Network ("NCCN") to include percutaneous cryoablation as a treatment option in its breast cancer guidelines, potentially broadening the range of treatment options available to eligible patients.

Financial Results for the Nine Months Ended September 30, 2026

Total revenues for the nine months ended September 30, 2026 increased approximately 26% to $2.6 million, compared to $2.1 million for the corresponding period in 2025.

Gross profit for the nine months ended September 30, 2026 increased approximately 22% to $762,000, compared to $626,000 in the corresponding period of 2025.

Research and development expenses for the nine months ended September 30, 2026 were $6.5 million, compared to $5.1 million in the corresponding period of 2025, primarily reflecting increased expenses related to the ChoICE Study and other clinical and development activities.

Sales and marketing expenses were $3.6 million for the nine months ended September 30, 2026, compared to $3.0 million in the corresponding period of 2025, primarily reflecting the continued expansion of the Company's U.S. commercial activities.

General and administrative expenses were $3.5 million for the nine months ended September 30, 2026, compared to $3.3 million in the corresponding period of 2025.

Operating loss for the nine months ended September 30, 2026 was $12.9 million, compared to $10.8 million in the corresponding period of 2025.

Net loss for the nine months ended September 30, 2026, was $12.9 million, compared to $10.8 million in the corresponding period of 2025.

As of September 30, 2026, the Company's cash and cash equivalents totaled approximately $8.2 million, and shareholders' equity was approximately $8.7 million.

Conference call & webcast info: 

Wednesday, November 18, 2026, at 10:00 am EST
US: 1-888-407-2553
Israel/International: +972-3-918-0696
A live webcast will be available at: https://www.veidan-conferenceing.com/icecure
A recording of the webcast will be available at: https://ir.icecure-medical.com/

About IceCure Medical

IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, as a safe and effective minimally invasive option to surgical tumor removal, with the primary focus areas being breast, kidney, bone and lung cancer. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.

ProSense® cryoablation became the first-and-only medical device cleared by the FDA for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible for surgery.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. For example, the Company is using forward-looking statements when it discusses its belief that the first nine months of 2026 demonstrate the progress the Company has made in translating its regulatory and clinical achievements into commercial growth; that the ChoICE Study is building the clinical foundation for broader adoption of ProSense®; that the Company's developments position it to continue driving physician adoption and expanding patient access to ProSense®; the continued expansion of its U.S. commercial footprint, active installed base clinic support personnel and physician adoption; the addition of IRB-approved U.S. clinical sites for the CHoICE Study to support physician adoption; and the belief that professional recognition of cryoablation through the petition submitted by the SIO can potentially broaden the range of treatment options available to eligible patients. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Relations:

Meir Peleg, CFO

[email protected]

+1-888-902-5716

ICECURE MEDICAL LTD.


CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION






As of
September 30,
2026



As of
December 31,
2025




(Unaudited)







U.S. dollars in thousands









ASSETS







CURRENT ASSETS







     Cash and cash equivalents



8,220




8,897


     Trade receivables



391




331


     Inventory



2,578




2,625


     Prepaid expenses and other receivables



1,298




752


Total current assets



12,487




12,605











NON-CURRENT ASSETS









     Right-of-use assets



729




239


     Property and equipment, net



940




993


     Long-term restricted deposits



53




51


Total non-current assets



1,722




1,283


TOTAL ASSETS



14,209




13,888











LIABILITIES AND SHAREHOLDERS' EQUITY


















CURRENT LIABILITIES









     Trade payables



1,071




863


     Lease liabilities



255




204


     Employees and employees related benefits



3,024




2,659


     Other current liabilities



633




1,098


Total current liabilities



4,983




4,824











NON-CURRENT LIABILITIES









     Long-term lease liabilities



452




13


Total non-current liabilities



452




13











SHAREHOLDERS' EQUITY









Ordinary shares, No par value; Authorized 2,500,000,000 shares; Issued and
outstanding: 5,563,265 shares and 2,437,410 shares as of September 30,
2026 and December 31, 2025, respectively









     Additional paid-in capital



142,205




129,487


     Accumulated deficit



(133,431)




(120,436)


     Total shareholders' equity



8,774




9,051


     TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY



14,209




13,888


ICECURE MEDICAL LTD.


CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS






Nine months ended
September 30,




2026



2025




U.S. dollars in thousands
(except per share data)


Revenues



2,642




2,100


Cost of revenues



1,880




1,474


Gross profit



762




626


Research and development expenses



6,557




5,137


Sales and marketing expenses



3,669




3,061


General and administrative expenses



3,527




3,306


Operating loss



12,991




10,878


Finance expenses (income), net



4




(67)











Net loss and comprehensive loss



12,995




10,811


Basic and diluted net loss per share



3.57




5.4


Weighted average number of shares outstanding used in
computing basic and diluted loss per share



3,637,322




2,018,573


ICECURE MEDICAL LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS




Nine months ended
September 30,




2026



2025





U.S. dollars in
thousands


Cash flows from operating activities
















Net loss


(12,995)



(10,811)



Adjustments to reconcile net loss to net cash used in operating activities:










Depreciation



207




224



Share-based compensation



687




1,102



Exchange rate changes in cash and cash equivalents and long-term restricted
deposits



(24)




118



Other finance cost



-




(34)



Changes in assets and liabilities:










Decrease (increase) in trade receivables



(60)




117



Decrease (increase) in prepaid expenses and other receivables



(546)




145



Decrease (increase) in inventory



47




(723)



Decrease in right of use assets



228




251



Increase (decrease) in trade payables



208




(81)



Decrease in lease liabilities



(227)




(212)



Increase in employees and employees related liabilities



365




595



Decrease in other current liabilities



(465)




(246)



Net cash used in operating activities



(12,575)




(9,555)













Cash flows from investing activities










Investment in short-term deposits



-




(5,000)



Purchase of property and equipment



(154)




(31)



Net cash used in investing activities



(154)




(5,031)













Cash flows from financing activities:










Proceeds from issuance of ordinary shares, warrants and pre-funded warrants, net
of issuance costs



12,020




12,114



Proceeds from exercise of warrants and pre-funded warrants



10




-



Net cash provided by financing activities



12,030




12,114













Decrease in cash and cash equivalents



(699)




(2,472)



Cash and cash equivalents at beginning of the year



8,897




7,564



Effect of exchange rate fluctuations on balances of cash and cash equivalents



22




(121)



Cash and cash equivalents at end of period



8,220




4,971













Non-cash activities










Obtaining a right-of-use asset in exchange for a lease liability



718




41



SOURCE IceCure Medical